drugset / Trial / NCT03100825

A Long-term Safety Study of QVM149 in Japanese Patients With Asthma

NCT03100825

Phase 3 Completed 96 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.

Timeline

Start
2017-04-28
Primary completion
2018-09-18
Completion
2019-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject QVM149 Unknown 50 ug Inhaled
Subject QVM149 Unknown 150 ug Inhaled
Subject QVM149 Unknown 160 ug Inhaled

Indications